228 related articles for article (PubMed ID: 32759233)
1. A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity.
Huang FY; Wang JY; Dai SZ; Lin YY; Sun Y; Zhang L; Lu Z; Cao R; Tan GH
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32759233
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3α Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity.
Wang JY; Chen H; Dai SZ; Huang FY; Lin YY; Wang CC; Li L; Zheng WP; Tan GH
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256516
[TBL] [Abstract][Full Text] [Related]
3. Microencapsulation of tumor lysates and live cell engineering with MIP-3α as an effective vaccine.
Huang FY; Huang FR; Chen B; Liu Q; Wang H; Zhou SL; Zhao HG; Huang YH; Lin YY; Tan GH
Biomaterials; 2015; 53():554-65. PubMed ID: 25890751
[TBL] [Abstract][Full Text] [Related]
4. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth.
Fushimi T; Kojima A; Moore MA; Crystal RG
J Clin Invest; 2000 May; 105(10):1383-93. PubMed ID: 10811846
[TBL] [Abstract][Full Text] [Related]
5. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.
Furumoto K; Soares L; Engleman EG; Merad M
J Clin Invest; 2004 Mar; 113(5):774-83. PubMed ID: 14991076
[TBL] [Abstract][Full Text] [Related]
6. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro.
Burke S; Shergold A; Elder MJ; Whitworth J; Cheng X; Jin H; Wilkinson RW; Harper J; Carroll DK
Cancer Immunol Immunother; 2020 Jun; 69(6):1015-1027. PubMed ID: 32088771
[TBL] [Abstract][Full Text] [Related]
8. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.
Koks CA; Garg AD; Ehrhardt M; Riva M; Vandenberk L; Boon L; De Vleeschouwer S; Agostinis P; Graf N; Van Gool SW
Int J Cancer; 2015 Mar; 136(5):E313-25. PubMed ID: 25208916
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo.
Xu Q; Rangaswamy US; Wang W; Robbins SH; Harper J; Jin H; Cheng X
Int J Cancer; 2020 Jan; 146(2):531-541. PubMed ID: 31584185
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells.
Ye T; Jiang K; Wei L; Barr MP; Xu Q; Zhang G; Ding C; Meng S; Piao H
Am J Cancer Res; 2018; 8(8):1514-1527. PubMed ID: 30210920
[TBL] [Abstract][Full Text] [Related]
11. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
12. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy.
Vigil A; Martinez O; Chua MA; García-Sastre A
Mol Ther; 2008 Nov; 16(11):1883-90. PubMed ID: 18714310
[TBL] [Abstract][Full Text] [Related]
13. Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model.
Gordy JT; Luo K; Zhang H; Biragyn A; Markham RB
J Immunother Cancer; 2016; 4():96. PubMed ID: 28018602
[TBL] [Abstract][Full Text] [Related]
14. Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy.
Schirrmacher V; van Gool S; Stuecker W
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361831
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
16. Localization of distinct Peyer's patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3alpha, MIP-3beta, and secondary lymphoid organ chemokine.
Iwasaki A; Kelsall BL
J Exp Med; 2000 Apr; 191(8):1381-94. PubMed ID: 10770804
[TBL] [Abstract][Full Text] [Related]
17. Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells.
Wang X; Shao X; Gu L; Jiang K; Wang S; Chen J; Fang J; Guo X; Yuan M; Shi J; Ding C; Meng S; Xu Q
J Cell Mol Med; 2020 Apr; 24(7):4286-4297. PubMed ID: 32100392
[TBL] [Abstract][Full Text] [Related]
18. STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells.
Shao X; Wang X; Guo X; Jiang K; Ye T; Chen J; Fang J; Gu L; Wang S; Zhang G; Meng S; Xu Q
Front Oncol; 2019; 9():436. PubMed ID: 31192135
[No Abstract] [Full Text] [Related]
19. MIP-3alpha transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity.
Bonnotte B; Crittenden M; Larmonier N; Gough M; Vile RG
J Immunol; 2004 Oct; 173(8):4929-35. PubMed ID: 15470034
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy.
Tian L; Liu T; Jiang S; Cao Y; Kang K; Su H; Ren G; Wang Z; Xiao W; Li D
Gene Ther; 2023 Feb; 30(1-2):64-74. PubMed ID: 34602608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
